PODCAST

Oncology and Hematology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Diagnosing and Staging Non-Small Cell Lung Cancer:...

Oncology and Hematology ·

2025/08/19

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jeffrey B. Velotta, MD, FACS Guest: Anne Gonzalez, MD, M.Sc. For patients with non-small cell lung cancer, staging accuracy is critical in guiding treatment decisions that can significantly affect outcomes. In this expert-led discussion, Dr. Gerard Silvestri sits down with Drs. Anne Gonzalez and Jeffrey Velotta break down what clinicians need to know, including how to perform thorough EBUS staging, why PET scans alone aren’t

00:00:00

Optimizing NSCLC Care: Advances in Lung Biopsy and...

Oncology and Hematology ·

2025/08/19

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri

00:00:00

Redefining Cancer Care with Functional Precision...

Oncology and Hematology ·

2025/08/14

Host: Matt Birnholz, MD Guest: Jim Foote, MBA Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable insights for relapsed and resistant cancer and empowers oncologists with faster, more targeted decision making.

00:00:00

Biomarker Predicts Response to BCMA CAR T-Cell...

Oncology and Hematology ·

2025/08/11

Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median

00:00:00

Optimizing Colorectal Cancer Screening: A Stress Test...

Oncology and Hematology ·

2025/08/08

Guest: Pedro Nascimento de Lima, PhD Conflicting colorectal cancer screening (CRC) guidelines have sometimes led to confusion over optimal starting ages and strategies. Join Dr. Pedro Nascimento de Lima as he walks through a comprehensive modeling study that tested 26 different strategies over 4,000 scenarios to test how and when it is most effective to screen. Dr. Nascimento de Lima is an Engineer at RAND, a Professor at the RAND School of Public Policy, and an investigator with the

00:00:00

Optimizing Second-Line CAR T Decisions in R/R Large...

Oncology and Hematology ·

2025/08/07

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is

00:00:00

Supplement Use for Colorectal Cancer Prevention:...

Oncology and Hematology ·

2025/08/06

Guest: Reid Ness, MD According to the NCCN Guidelines for Colorectal Cancer Screening, there is mixed evidence around the impact of vitamin D, calcium, folate, and aspirin on colorectal cancer risk. Join Dr. Reid Ness as he discusses considerations for recommending these supplements based on patient-specific factors. Dr. Ness is an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, faculty with the Vanderbilt Ingram Cancer Center, and the

00:00:00

Putting Patients First: Personalized Care in...

Oncology and Hematology ·

2025/08/05

Host: Ashley Baker, MSN, PMHNP Guest: Giancarlo Moscol, M.D. Metastatic breast cancer treatment isn't one-size-fits-all. Providers must carefully balance clinical outcomes, toxicity, and patient lifestyle and preferences. Dr. Giancarlo Moscol joins Ms. Ashley Baker to outline a structured, three-tiered decision-making process that weighs treatment efficacy, side effect burden, and real-world logistics like administration route and patient support systems. Dr. Moscol is an Associate

00:00:00

Disaster-Proofing Colorectal Cancer Screening: What...

Oncology and Hematology ·

2025/08/05

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gloria Coronado, PhD Colorectal cancer screening saw significant disruptions during the COVID-19 pandemic, a challenge that has also been reflected during natural disasters such as hurricanes and wildfires. Dr. Gloria Coronado joins Dr. Charles Turck to discuss how these kinds of crises impact screening rates and how a focus on community-based care, telehealth and home-based testing, and targeted efforts for underserved populations

00:00:00

Debunking CAR T-Cell Myths: The Realities of Patient...

Oncology and Hematology ·

2025/08/04

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the

00:00:00

Boosting Colorectal Cancer Screening in Rural...

Oncology and Hematology ·

2025/08/01

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gloria Coronado, PhD Guest: Amanda Petrik, PhD The SMARTER CRC trial evaluated mailed fecal immunochemical (FIT) outreach and patient navigation strategies across rural clinics, analyzing how implementation factors like clinic-sent letters, consistent FIT usage, and active participation in health plan meetings impacted screening outcomes. Two authors of the study, Dr. Gloria Coronado and Dr. Amanda Petrik, join Dr. Charles Turck

00:00:00

DESTINY-Breast04 Findings: T-DXd and Quality of Life...

Oncology and Hematology ·

2025/07/31

Host: Marlene Mimi Maeusli, PhD. New insights from DESTINY-Breast04 highlight how trastuzumab deruxtecan (T-DXd) not only extends survival but also delays symptom deterioration in HER2-low metastatic breast cancer. In this AudioAbstract, Dr. Mimi Maeusli discusses key takeaways from the outcomes analysis and what they mean for treatment planning and patient-centered care.

00:00:00

Clinical Decision-Making in Metastatic Breast Cancer:...

Oncology and Hematology ·

2025/07/31

Host: Ashley Baker, MSN, PMHNP Guest: Giancarlo Moscol, M.D. Effective treatment sequencing in patients with metastatic breast cancer is critical for maximizing clinical benefit and maintaining quality of life. Ms. Ashley Baker sits down with Dr. Giancarlo Moscol to discuss how to approach sequencing decisions based on tumor biology, disease progression patterns, and actionable mutations. Dr. Moscol is an Associate Professor in the Department of Breast Medical Oncology

00:00:00

Pediatric Sickle Cell Disease: Analyzing Trends in...

Oncology and Hematology ·

2025/07/29

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral

00:00:00

Cardiac Complications in Sickle Cell Disease:...

Oncology and Hematology ·

2025/07/21

Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. Parul Rai, a physician in the Department of Hematology at St. Jude’s Hospital in Memphis, Tennessee, to learn about current research, early

00:00:00

Integrating IV Iron into Cancer Care: An Expert...

Oncology and Hematology ·

2025/06/11

Host: Brian P. McDonough, MD, FAAFP Guest: George M. Rodgers, MD, PhD Guest: Patricia A. Ford, MD Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, and patient burden of CRA/CIA, as well as the prominent role of iron deficiency (ID)

00:00:00

Subcutaneous Cancer Immunotherapy at Home:...

Oncology and Hematology ·

2025/06/10

Guest: Jorge Nieva, MD As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how this delivery model could impact clinical trials and cancer care is Dr. Jorge Nieva, Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.

00:00:00

Unpacking the Logistics of At-Home Subcutaneous...

Oncology and Hematology ·

2025/06/05

Guest: Jorge Nieva, MD Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like cost, payer preferences, and patient safety. Tune in to hear Dr. Jorge Nieva discuss these key factors and considerations impacting the implementation of at-home subcutaneous cancer immunotherapy delivery. Dr. Nieva is an Associate Professor of Clinical Medicine at the University of Southern

00:00:00

First Results From Cohort 4 of the SunRISe-1 Trial

Oncology and Hematology ·

2025/05/01

This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along

00:00:00

Trial in Progress: Phase 3 MoonRISe-3 Study

Oncology and Hematology ·

2025/05/01

227 results

Oncology and Hematology

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe